BioNxt Solutions Inc. (CVE:BNXT)

PRESS RELEASE

published on 02/19/2025 at 09:05, 1 year 8 months ago

BioNxt Solutions Unveils Accelerated 90-Day Plan: Global Patent Advancements, MS Clinical Trial, and Anti-Aging Expansion
BioNxt Solutions Inc. announces major milestones for the next 90 days, including global patent filings, bioequivalence study for MS treatment, and expansion into longevity & anti-aging sector

BioNxt Solutions Inc. Patents Longevity Anti-Aging Bioequivalence Study
BRIEF

published on 01/21/2025 at 09:10, 1 year 9 months ago

BioNxt's Strategic Move to Gen-Plus Laboratory in Munich

Pharmaceutical Innovation R&D Expansion BioNxt Solutions Drug Delivery Systems Gen-Plus Laboratory
BRIEF

published on 01/21/2025 at 09:10, 1 year 9 months ago

Déménagement stratégique de BioNxt vers le laboratoire Gen-Plus à Munich

Innovation Pharmaceutique Solutions BioNxt Systèmes D'administration De Médicaments Laboratoire Gen-Plus Expansion De La R&D
PRESS RELEASE

published on 01/21/2025 at 09:05, 1 year 9 months ago

BioNxt Accelerates R&D with Move to Gen-Plus Laboratory in Munich, Germany, Expanding Drug Delivery Research Capabilities
BioNxt Solutions Inc. relocates R&D activities to Gen-Plus CRDO in Munich, Germany, enhancing capabilities and fostering collaborations in drug delivery systems, neurodegenerative therapeutics, and biomedical tech

BioNxt Solutions Inc. Munich R&D Activities Drug Delivery Systems Gen-Plus CRDO
BRIEF

published on 12/19/2024 at 09:10, 1 year 10 months ago

BioNxt Solutions Expands Patent Portfolio for Drug Delivery Innovations

Multiple Sclerosis BioNxt Solutions Sublingual Delivery Patent Expansion Drug Innovation
BRIEF

published on 12/19/2024 at 09:10, 1 year 10 months ago

BioNxt Solutions élargit son portefeuille de brevets pour ses innovations en matière d'administration de médicaments

Sclérose En Plaques Innovation Pharmaceutique Solutions BioNxt Extension Du Brevet Administration Sublinguale
PRESS RELEASE

published on 12/19/2024 at 09:05, 1 year 10 months ago

BioNxt Solutions Expands Patent Protection for Drug Delivery Innovations Backed by Positive IPRP
BioNxt Solutions Inc. expands its intellectual property portfolio with new international patents for sublingual delivery technologies targeting autoimmune neurodegenerative diseases. The company aims to bring patient-friendly therapies to individuals affected by these diseases

BioNxt Solutions Inc. Intellectual Property Patents Autoimmune Neurodegenerative Diseases Sublingual Delivery Technologies
BRIEF

published on 12/09/2024 at 09:10, 1 year 11 months ago

BioNxt Solutions Advances BNT23001 for MS Treatment

Clinical Trials Drug Development Multiple Sclerosis BioNxt Solutions BNT23001
BRIEF

published on 12/09/2024 at 09:10, 1 year 11 months ago

BioNxt Solutions développe le BNT23001 pour le traitement de la sclérose en plaques

Essais Cliniques Sclérose En Plaques Développement De Médicaments Solutions BioNxt BNT23001
PRESS RELEASE

published on 12/09/2024 at 09:05, 1 year 11 months ago

BioNxt Solutions Reports Progress on BNT23001 Development for Multiple Sclerosis Treatment
BioNxt Solutions Inc. achieves key milestones in the development of BNT23001, a sublingual thin-film formulation of Cladribine for Multiple Sclerosis treatment, paving the way for clinical trials and regulatory submissions in 2025

Clinical Trials BioNxt Solutions Inc. Multiple Sclerosis Sublingual Thin-Film BNT23001

Published on 11/10/2026 at 02:45, 1 hour 7 minutes ago

Presentation to Zurich Precious Metals Summit
Published on 11/09/2026 at 23:10, 4 hours 42 minutes ago

Ur-Energy Reports Third Quarter 2026 Results
Published on 11/09/2026 at 23:00, 4 hours 52 minutes ago

LNG Energy Group Announces Issuance of Third Partial Revocation Order and Proposed Shares-for-Debt Settlement
Published on 11/09/2026 at 22:32, 5 hours 20 minutes ago

Announces Extension for Closing of Private Placement of Convertible Promissory Notes
Published on 11/09/2026 at 22:15, 5 hours 37 minutes ago

Goldcliff Announces Closing of the Second and Final Tranche of its "LIFE" Offering and Completion of Drilling at Kettle Valley

View all ACCESSWIRE

Published on 11/10/2026 at 01:20, 2 hours 31 minutes ago

US defence customer steps up orders and first graphene oxide orders secured
Published on 11/09/2026 at 23:35, 4 hours 16 minutes ago

KPS to Acquire MM Packaging from MM Group
Published on 11/09/2026 at 22:54, 4 hours 58 minutes ago

EQS-Adhoc: Northern Data Group reports Q3 2026 and raises its FY 2026 revenue outlook communicated on 17 June 2026
Published on 11/09/2026 at 22:10, 5 hours 41 minutes ago

Quantinuum to Participate in the Cantor Convergence 4th Annual Crypto, FinTech, AI & Energy Infrastructure Conference
Published on 11/09/2026 at 22:05, 5 hours 47 minutes ago

Mayr-Melnhof Karton AG: MM Group to sell majority stake in its Packaging business to KPS Capital Partners and plans a special distribution to shareholders

View all EQS

Published on 11/09/2026 at 18:30, 9 hours 22 minutes ago

Air Liquide has successfully issued a CHF 390 million multi-tranche bond
Published on 11/09/2026 at 18:30, 9 hours 22 minutes ago

Air Liquide a réalisé avec succès une émission obligataire multi-tranches de 390 millions de CHF
Published on 11/09/2026 at 17:45, 10 hours 7 minutes ago

Weekly share buyback
Published on 11/09/2026 at 17:45, 10 hours 7 minutes ago

Déclaration hebdomadaire de rachat d'actions
Published on 11/09/2026 at 17:45, 10 hours 7 minutes ago

Déclaration des droits de vote à fin octobre 2026

View all LES ECHOS COMFI WIRE

News